Literature DB >> 23001823

Differential mechanisms of tumor progression in clones from a single heterogeneous human melanoma.

Walburga Croteau1, Molly H Jenkins, Siying Ye, David W Mullins, Constance E Brinckerhoff.   

Abstract

We used vertical growth phase (VGP) human VMM5 melanoma cells to ask whether the tumor microenvironment could induce matrix metalloproteinase-1 (MMP-1) in vivo, and whether this induction correlated with metastasis. We isolated two clones from parental VMM5 cells: a low MMP-1 producing clone (C4) and high producing clone (C9). When these clones were injected orthotopically (intradermally) into nude mice, both were equally tumorigenic and produced equivalent and abundant amounts of MMP-1. However, the tumors from the C4 clones displayed different growth kinetics and distinct profiles of gene expression from the C9 population. The C4 tumors, which had low MMP-1 levels in vitro, appeared to rely on growth factors and cytokines in the microenvironment to increase MMP-1 expression in vivo, while MMP-1 levels remained constant in the C9 tumors. C9 cells, but not C4 cells, grew as spheres in culture and expressed higher levels of JARID 1B, a marker associated with melanoma initiating cells. We conclude that VMM5 melanoma cells exhibit striking intra-tumor heterogeneity, and that the tumorigenicity of these clones is driven by different molecular pathways. Our data suggest that there are multiple mechanisms for melanoma progression within a tumor, which may require different therapeutic strategies.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23001823      PMCID: PMC3864099          DOI: 10.1002/jcp.24225

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  39 in total

Review 1.  Matrix metalloproteinases: a tail of a frog that became a prince.

Authors:  Constance E Brinckerhoff; Lynn M Matrisian
Journal:  Nat Rev Mol Cell Biol       Date:  2002-03       Impact factor: 94.444

2.  Low-level monocyte chemoattractant protein-1 stimulation of monocytes leads to tumor formation in nontumorigenic melanoma cells.

Authors:  M Nesbit; H Schaider; T H Miller; M Herlyn
Journal:  J Immunol       Date:  2001-06-01       Impact factor: 5.422

3.  High expression levels of collagenase-1 and stromelysin-1 correlate with shorter disease-free survival in human metastatic melanoma.

Authors:  Johanna Nikkola; Pia Vihinen; Tatyana Vlaykova; Marjo Hahka-Kemppinen; Veli-Matti Kähäri; Seppo Pyrhönen
Journal:  Int J Cancer       Date:  2002-02-01       Impact factor: 7.396

4.  Loss of heterozygosity on chromosome 11q22-23 in melanoma is associated with retention of the insertion polymorphism in the matrix metalloproteinase-1 promoter.

Authors:  W W Noll; D R Belloni; J L Rutter; C A Storm; A R Schned; L Titus-Ernstoff; M S Ernstoff; C E Brinckerhoff
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

Review 5.  Interstitial collagenases as markers of tumor progression.

Authors:  C E Brinckerhoff; J L Rutter; U Benbow
Journal:  Clin Cancer Res       Date:  2000-12       Impact factor: 12.531

6.  Transforming growth factor-beta1 increases survival of human melanoma through stroma remodeling.

Authors:  C Berking; R Takemoto; H Schaider; L Showe; K Satyamoorthy; P Robbins; M Herlyn
Journal:  Cancer Res       Date:  2001-11-15       Impact factor: 12.701

7.  Monocyte chemoattractant protein-1 enhances gene expression and synthesis of matrix metalloproteinase-1 in human fibroblasts by an autocrine IL-1 alpha loop.

Authors:  T Yamamoto; B Eckes; C Mauch; K Hartmann; T Krieg
Journal:  J Immunol       Date:  2000-06-15       Impact factor: 5.422

Review 8.  An evidence-based staging system for cutaneous melanoma.

Authors:  Charles M Balch; Seng-Jaw Soong; Michael B Atkins; Antonio C Buzaid; Natale Cascinelli; Daniel G Coit; Irvin D Fleming; Jeffrey E Gershenwald; Alan Houghton; John M Kirkwood; Kelly M McMasters; Martin F Mihm; Donald L Morton; Douglas S Reintgen; Merrick I Ross; Arthur Sober; John A Thompson; John F Thompson
Journal:  CA Cancer J Clin       Date:  2004 May-Jun       Impact factor: 508.702

9.  Pro-matrix metalloproteinase-2 transfection increases orthotopic primary growth and experimental metastasis of MDA-MB-231 human breast cancer cells in nude mice.

Authors:  Angus M Tester; Mark Waltham; Se-Jeong Oh; Seog-Nyeon Bae; Margaret M Bills; Emma C Walker; Francis G Kern; William G Stetler-Stevenson; Marc E Lippman; Erik W Thompson
Journal:  Cancer Res       Date:  2004-01-15       Impact factor: 12.701

10.  Global analysis of BRAFV600E target genes in human melanocytes identifies matrix metalloproteinase-1 as a critical mediator of melanoma growth.

Authors:  Byungwoo Ryu; Whei F Moriarty; Megan J Stine; Amena DeLuca; Dave S Kim; Alan K Meeker; Landon D Grills; Rebecca A Switzer; Mark S Eller; Rhoda M Alani
Journal:  J Invest Dermatol       Date:  2011-03-31       Impact factor: 8.551

View more
  9 in total

1.  What are the therapeutic implications of increased collagen expression in melanoma cells treated with vemurafenib?

Authors:  Constance E Brinckerhoff
Journal:  Melanoma Manag       Date:  2016-02-18

Review 2.  Cancer Stem Cells (CSCs) in melanoma: There's smoke, but is there fire?

Authors:  Constance E Brinckerhoff
Journal:  J Cell Physiol       Date:  2017-03-06       Impact factor: 6.384

3.  Multiple murine BRaf(V600E) melanoma cell lines with sensitivity to PLX4032.

Authors:  Molly H Jenkins; Shannon M Steinberg; Matthew P Alexander; Jan L Fisher; Marc S Ernstoff; Mary Jo Turk; David W Mullins; Constance E Brinckerhoff
Journal:  Pigment Cell Melanoma Res       Date:  2014-03-06       Impact factor: 4.693

4.  CXCR3 signaling in BRAFWT melanoma increases IL-8 expression and tumorigenicity.

Authors:  Molly H Jenkins; Constance E Brinckerhoff; David W Mullins
Journal:  PLoS One       Date:  2015-03-23       Impact factor: 3.240

5.  BRAF(V600E) melanoma cells secrete factors that activate stromal fibroblasts and enhance tumourigenicity.

Authors:  C A Whipple; C E Brinckerhoff
Journal:  Br J Cancer       Date:  2014-08-12       Impact factor: 7.640

6.  The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.

Authors:  Molly H Jenkins; Walburga Croteau; David W Mullins; Constance E Brinckerhoff
Journal:  Matrix Biol       Date:  2015-05-16       Impact factor: 11.583

7.  A slow-cycling subpopulation of melanoma cells with highly invasive properties.

Authors:  M Perego; M Maurer; J X Wang; S Shaffer; A C Müller; K Parapatics; L Li; D Hristova; S Shin; F Keeney; S Liu; X Xu; A Raj; J K Jensen; K L Bennett; S N Wagner; R Somasundaram; M Herlyn
Journal:  Oncogene       Date:  2017-09-18       Impact factor: 9.867

8.  Heterogeneity of gene expression in murine squamous cell carcinoma development-the same tumor by different means.

Authors:  Noam Cohen; Nataly Kravchenko-Balasha; Shoshana Klein; Alexander Levitzki
Journal:  PLoS One       Date:  2013-03-18       Impact factor: 3.240

Review 9.  Intratumor and Intertumor Heterogeneity in Melanoma.

Authors:  Tomasz M Grzywa; Wiktor Paskal; Paweł K Włodarski
Journal:  Transl Oncol       Date:  2017-10-24       Impact factor: 4.243

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.